SHOT.NASDAQSafety Shot, INC

S-1: Safety Shot Inc. Files for Resale of 1,233,507 Common Shares

Sentiment:

S-1 Filing


Safety Shot Inc. is registering for resale 1,233,507 shares of its common stock by existing shareholders.

Capital raiseThe document details a potential capital raise through the sale of common stock and warrants.The company may offer and sell shares of its common stock, having an aggregate offering price of up to $5,000,000, through an Equity Disbursement Agreement with Maxim Group LLC.

Summary

  • Safety Shot Inc. has filed a registration statement for the resale of up to 1,233,507 shares of its common stock.
  • The shares are being offered by selling stockholders, including 3i LP (833,507 shares) and Paul L. Kessler (400,000 shares).
  • 3i LP received shares as part of a settlement agreement, while Paul L. Kessler received shares for services rendered.
  • The company will not receive any proceeds from the sale of these shares.
  • The document details various agreements, including a Securities Purchase Agreement with Eleazar Holdings, a Settlement Agreement with Bigger Capital, and a Consulting Agreement with Blue Capital S.A., LLC.
  • It also mentions a recent notice from Nasdaq regarding non-compliance with minimum bid price requirements.
  • An Arrangement Agreement with Yerbae Brands Corp. is outlined, involving the acquisition of Yerbae by Safety Shot.
  • The document includes information about the company's business, products, research and development, and intellectual property.
  • It also discusses government regulations affecting the company's products and operations.
  • The company has eight full-time employees and leases office space in Jupiter, FL.

Sentiment

Score: 4

Explanation: The document is largely factual and legal in nature, but the company's financial situation and ongoing legal challenges temper any positive outlook. The potential for dilution and the going concern warning contribute to a neutral to slightly negative sentiment.

Positives

  • The company has completed clinical trials showing a statistically significant reduction in BAC with its Sure Shot Dietary Supplement.
  • The company is actively pursuing new product formats and formulations.
  • The company has a diverse network of raw material suppliers.
  • The company is pursuing collaborations to license its intellectual property.
  • The company is working to regain compliance with Nasdaq listing requirements.

Negatives

  • The company will not receive any proceeds from the resale of shares by selling stockholders.
  • The company has a history of net losses and a large accumulated deficit.
  • The company is facing a Nasdaq notice regarding non-compliance with minimum bid price requirements.
  • The company is involved in several legal proceedings.
  • The company's auditor has expressed doubt about its ability to continue as a going concern.

Risks

  • The company may not be able to keep up with rapid technological changes.
  • Competition could adversely affect the company's business.
  • The company may be unable to develop and maintain its brand and reputation.
  • The company is subject to government regulation, and unfavorable changes could substantially harm its business.
  • The company depends heavily on key personnel, and turnover of key senior management could harm its business.
  • The company's products may not meet health and safety standards or could become contaminated.
  • The sale of the company's products involves product liability and related risks.
  • The company's success will depend upon its ability to create and expand its brand awareness.
  • The company must develop and introduce new products to succeed.
  • Adverse publicity associated with the company's products or ingredients could adversely affect its sales and revenue.
  • The company may not meet its product development and commercialization milestones.
  • The company's operations in international markets involve inherent risks that it may not be able to control.
  • Compliance with new and existing laws and governmental regulations could increase the company's costs significantly and adversely affect its results of operations.
  • The company's reliance on third parties to manufacture and supply its products may harm its business.
  • The company may not be able to establish relationships with licensees or collaborators to carry out sales, marketing, and distribution functions.
  • Natural disasters and other events beyond the company's control could materially adversely affect it.
  • The company has a limited operating history upon which investors can evaluate its future prospects.
  • The company's accountant has indicated doubt about its ability to continue as a going concern.
  • The company may not be able to obtain additional financing on terms acceptable to it.
  • The company is an emerging growth company and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make its common stock less attractive to investors.
  • The requirements of being a public company may strain the company's resources and distract its management.
  • The company may not use the net proceeds from any offerings effectively.
  • The company's management has limited experience in managing the day-to-day operations of a public company.
  • Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.
  • Certain of the company's stockholders hold a significant percentage of its outstanding voting securities.
  • If securities or industry analysts publish inaccurate or unfavorable research about the company's business, its stock price could decline.
  • The company does not intend to pay dividends for the foreseeable future.
  • The company's Second Amended and Restated Certificate of Incorporation contains an exclusive forum provision for certain claims.
  • The company's issuance of additional common stock or preferred stock may cause its common stock price to decline.
  • Anti-takeover provisions in the company's charter and bylaws may prevent or frustrate attempts by stockholders to change the board of directors or current management.
  • The company's common stock may become subject to the SEC's penny stock rules.

Future Outlook

The company plans to continue to develop new flavors for its current SKUs and conduct additional research studies.

Industry Context

The company operates in the competitive consumer packaged goods industry, specifically focusing on dietary supplements and beverages.

Legal Proceedings

  • The company is involved in several legal proceedings, including actions with 3i LP, Bigger Capital, Intracoastal Capital, Sabby Volatility Warrant Master Fund Ltd., and Coachella Music Festival, LLC.

Related Party Transactions

  • The document mentions transactions with related parties, including loans from directors and consulting agreements with entities affiliated with officers.

Stakeholder Impact

  • Shareholders may experience dilution due to the issuance of new shares.
  • The company's ability to execute its business plan and achieve profitability is crucial for all stakeholders.
  • Employees' job security and compensation may be affected by the company's financial performance.

Next Steps

  • The company needs to regain compliance with Nasdaq's minimum bid price requirement by July 1, 2025.
  • The company needs to obtain Shareholder Approval for the Yerbae Brands Corp. acquisition.
  • The company needs to file a Notice of Discontinuance for the 3i LP Action within ten (10) days of effectiveness of the registration statement.

Key Dates

DateDescription
2023-08-14SRM consummated its Initial Public Offering (IPO).
2024-01-02Company received a notice from Nasdaq regarding non-compliance with minimum bid price requirement.
2025-01-07Company entered into a definitive Arrangement Agreement with Yerbae Brands Corp.
2025-01-14Company entered into the Intracoastal Settlement Agreement.
2025-01-17Company entered into a Securities Purchase Agreement for the purchase of 2,277,389 shares.
2025-01-18Company entered into a Consulting Agreement with Blue Capital S.A., LLC.
2025-01-20Company entered into the Bigger Settlement Agreement.
2025-02-04Company entered into the Securities Purchase Agreement with Eleazar Holdings.
2025-02-21Company entered into Amendment No. 1 to the Blue Capital Consulting Agreement.
2025-04-01Company entered into the Amendment to the Bigger Settlement Agreement.
2025-04-23Company entered into the Stipulation of Settlement with 3i LP.
2025-05-02Company entered into an Exchange Agreement with Core 4 Capital Corp.
2025-05-16Last reported sale price of common stock was approximately $0.41 per share.
2025-07-01Deadline for the Company to regain compliance with Nasdaq minimum bid price requirement.

Keywords

common stock, securities, warrants, registration, settlement, agreement, company, shares, officer, director

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.